MCID: ANG046
MIFTS: 52

Angioimmunoblastic T-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 54 60 56 15 17
Immunoblastic Lymphadenopathy 54 60 45 17
T-Cell Lymphoma, Aild Type 54 60
Lymphogranulomatosis X 54 60
Angioimmunoblastic Lymphadenopathy 74
Aitl 54
Ailt 60

Characteristics:

Orphanet epidemiological data:

60
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0111147
MeSH 45 D007119
NCIt 51 C7528
SNOMED-CT 69 835009
ICD10 34 C86.5
ICD10 via Orphanet 35 C86.5
UMLS via Orphanet 75 C0020981
Orphanet 60 ORPHA86886
UMLS 74 C0020981

Summaries for Angioimmunoblastic T-Cell Lymphoma

Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to autoimmune lymphoproliferative syndrome, type v and composite lymphoma, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are T cell receptor signaling pathway and ICos-ICosL Pathway in T-Helper Cell. The drugs Prednisone and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 autoimmune lymphoproliferative syndrome, type v 30.6 BCL6 TIA1
2 composite lymphoma 30.4 BCL6 TIA1
3 lymphoma, hodgkin, classic 30.4 BCL6 MME
4 marginal zone b-cell lymphoma 30.3 BCL6 MME
5 burkitt lymphoma 30.1 BCL6 CXCL13 MME
6 b-cell lymphomas 29.8 BCL6 MME SYK TIA1
7 peripheral t-cell lymphoma 29.6 BCL6 CXCL13 ITK MME SYK TET2
8 angioimmunoblastic lymphadenopathy with dysproteinemia 11.8
9 lymphoma 11.3
10 diffuse large b-cell lymphoma 10.6
11 leukemia 10.5
12 lymphoproliferative syndrome 10.4
13 hypereosinophilic syndrome 10.4
14 heart lymphoma 10.3 BCL6 MME
15 intravascular large b-cell lymphoma 10.3 BCL6 MME
16 arthritis 10.3
17 follicular lymphoma 10.3
18 pure red-cell aplasia 10.3
19 pneumonia 10.3
20 vasculitis 10.3
21 plasma cell leukemia 10.3
22 testicular lymphoma 10.3 BCL6 MME
23 t-cell/histiocyte rich large b cell lymphoma 10.3 BCL6 MME
24 central nervous system hematologic cancer 10.3 BCL6 MME
25 acute salpingitis 10.2 CXCL13 MME
26 folic acid deficiency anemia 10.2 MME TET2
27 spondyloarthropathy 1 10.2
28 leukemia, chronic lymphocytic 2 10.2
29 leukemia, chronic lymphocytic 10.2
30 rheumatoid arthritis 10.2
31 ascites, chylous 10.2
32 mycosis fungoides 10.2
33 myelofibrosis 10.2
34 hemophagocytic lymphohistiocytosis 10.2
35 thrombocytopenia 10.2
36 lymphocytic leukemia 10.2
37 cardiac tamponade 10.2
38 spondylitis 10.2
39 evans' syndrome 10.2
40 polyarteritis nodosa 10.2
41 leukemia, b-cell, chronic 10.2
42 methotrexate-associated lymphoproliferative disorders 10.2
43 nodular lymphocyte predominant hodgkin lymphoma 10.2 BCL6 PDCD1
44 lymphoma, mucosa-associated lymphoid type 10.2 BCL6 CXCL13 MME
45 mature b-cell neoplasm 10.1 BCL6 MME
46 ileum cancer 10.1 MME TIA1
47 hashimoto thyroiditis 10.1
48 cryoglobulinemia 10.1
49 thyroiditis 10.1
50 cryptococcosis 10.1

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 BCL6 CXCL13 ICOS ITK PDCD1 SYK
2 immune system MP:0005387 9.9 BCL6 CXCL13 ICOS ITK MAF MME
3 endocrine/exocrine gland MP:0005379 9.87 BCL6 ICOS ITK PDCD1 SYK TBX21
4 liver/biliary system MP:0005370 9.35 BCL6 MME PDCD1 SYK TET2
5 neoplasm MP:0002006 9.02 ICOS IDH2 PDCD1 TBX21 TET2

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 53-03-2 5865
2
Ifosfamide Approved Phase 4,Phase 1,Phase 2,Early Phase 1 3778-73-2 3690
3
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-02-2 5743
6
Epirubicin Approved Phase 4 56420-45-2 41867
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 1177-87-3
9
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
10
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 23214-92-8 31703
12
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable 51-75-2 4033
13
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
14
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 31703
17
Pirarubicin Investigational Phase 4 72496-41-4
18 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
22 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
29 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
30 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 BB 1101 Phase 4,Phase 3,Phase 2,Early Phase 1
33 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
35
Isophosphamide mustard Phase 4,Phase 1,Phase 2,Early Phase 1 0
36 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Folate Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Vitamin B9 Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
45
alemtuzumab Approved, Investigational Phase 3,Phase 1,Phase 2 216503-57-0
46
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
47
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
48
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
49 Orange Approved Phase 3
50
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764

Interventional clinical trials:

(show top 50) (show all 256)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
4 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
11 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
12 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
15 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
16 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
17 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
19 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
20 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
21 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
22 Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
23 Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
24 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
25 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
27 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
28 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
29 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
30 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
31 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
32 A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
33 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
34 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
35 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
36 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
37 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
38 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
39 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
40 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
41 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
42 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine
43 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
44 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
45 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
46 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
47 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
48 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
49 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
50 Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Cochrane evidence based reviews: immunoblastic lymphadenopathy

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

42
T Cells, B Cells, Bone, Bone Marrow, Lymph Node, Endothelial, Liver

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 504)
# Title Authors Year
1
Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B-cell lymphoma or classical Hodgkin lymphoma: A histologic diagnostic pitfall. ( 30370547 )
2019
2
Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma. ( 30097855 )
2019
3
Chylous ascites, anti-interferon-gamma autoantibody, and angioimmunoblastic T-cell lymphoma: a rare but intriguing connection over Mycobacterium avium. ( 30083859 )
2019
4
EBV-Related Diffuse Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma ( 30066674 )
2019
5
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2019
6
The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH. ( 29621877 )
2019
7
Clinical spectrum, evolution and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. ( 30985955 )
2019
8
Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. ( 30980412 )
2019
9
Moving Toward Targeted Therapy in the Treatment of Angioimmunoblastic T-Cell Lymphoma. ( 30861369 )
2019
10
Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma. ( 30861367 )
2019
11
Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. ( 30861363 )
2019
12
Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases. ( 30809041 )
2019
13
Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation. ( 30732495 )
2019
14
Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma. ( 30648445 )
2019
15
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. ( 30630534 )
2019
16
Angioimmunoblastic T-Cell Lymphoma. ( 30596215 )
2019
17
Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. ( 30485406 )
2019
18
Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. ( 30279227 )
2018
19
Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr Virus positivity and its effects on clinicopathological features. ( 30240776 )
2018
20
Hemophagocytic lymphohistiocytosis presenting with annular erythema multiforme-like eruptions in a patient with angioimmunoblastic T cell lymphoma: A case report. ( 30186440 )
2018
21
B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. ( 30150635 )
2018
22
Angioimmunoblastic T-cell lymphoma presenting with extensive marrow plasmacytosis and hypergammaglobulinaemia: a diagnostic challenge. ( 30143343 )
2018
23
Methotrexate-associated lymphoproliferative disorders with angioimmunoblastic T-cell lymphoma-like features accompanied by gamma-heavy chain disease in a patient with rheumatoid arthritis. ( 29987858 )
2018
24
Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing. ( 29981867 )
2018
25
Secondary Cutaneous Epstein-Barr Virus-associated Diffuse Large B-cell Lymphoma with Hodgkin/Reed-Sternberg-like Cells in a Patient with Angioimmunoblastic T-cell Lymphoma. ( 29956714 )
2018
26
Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. ( 29909754 )
2018
27
Hypercalcemia as a rare presentation of angioimmunoblastic T cell lymphoma: a case report. ( 29673407 )
2018
28
Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. ( 29662631 )
2018
29
Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma. ( 29636953 )
2018
30
Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. ( 29493850 )
2018
31
Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review. ( 29480865 )
2018
32
Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. ( 29428971 )
2018
33
Florid Plasmacytosis in Angioimmunoblastic T Cell Lymphoma: A Diagnostic Conundrum. ( 29398831 )
2018
34
Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. ( 29339730 )
2018
35
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
36
Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. ( 29197996 )
2018
37
Epstein-Barr virus clonality and plasmacytosis in a patient with atypical angioimmunoblastic T cell lymphoma. ( 29189897 )
2018
38
Invasive Aspergillosis in Refractory Angioimmunoblastic T-Cell Lymphoma. ( 29129826 )
2018
39
A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma. ( 29048103 )
2018
40
Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. ( 28889481 )
2018
41
Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. ( 28832024 )
2018
42
Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma. ( 30701922 )
2018
43
Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome. ( 30592297 )
2018
44
Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. ( 30557716 )
2018
45
Angioimmunoblastic T-cell lymphoma mimicking diffuse large B-cell lymphoma. ( 30372708 )
2018
46
Systemic lupus erythematosus as the concomitant manifestation of angioimmunoblastic T-cell lymphoma. ( 25401231 )
2017
47
Pathological findings of lymphadenopathy in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic syndrome (DRESS): similarities with angioimmunoblastic T-cell lymphoma. ( 28120775 )
2017
48
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. ( 28115369 )
2017
49
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. ( 28082343 )
2017
50
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy. ( 28050005 )
2017

Variations for Angioimmunoblastic T-Cell Lymphoma

Cosmic variations for Angioimmunoblastic T-Cell Lymphoma:

9 (show top 50) (show all 181)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6498677 WDFY3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5163A>T p.L1721F 4:84765835-84765835 0
2 COSM6987215 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1625C>T p.P542L 16:2065544-2065544 0
3 COSM10995 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 0
4 COSM10650 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.529C>T p.P177S 17:7675083-7675083 0
5 COSM10687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.527G>A p.C176Y 17:7675085-7675085 0
6 COSM10654 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.637C>T p.R213* 17:7674894-7674894 0
7 COSM45626 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.501G>T p.Q167H 17:7675111-7675111 0
8 COSM10788 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.764T>G p.I255S 17:7674199-7674199 0
9 COSM45005 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.739A>G p.N247D 17:7674224-7674224 0
10 COSM10889 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.536A>G p.H179R 17:7675076-7675076 0
11 COSM43896 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.818G>C p.R273P 17:7673802-7673802 0
12 COSM43836 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.475G>C p.A159P 17:7675137-7675137 0
13 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.586C>T p.R196* 17:7674945-7674945 0
14 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.817C>T p.R273C 17:7673803-7673803 0
15 COSM35978 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.811C>T p.R271* 6:137877081-137877081 0
16 COSM6498674 TLR6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.1828G>T p.D610Y 4:38827646-38827646 0
17 COSM87190 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5696T>C p.L1899P 4:105276206-105276206 0
18 COSM4766127 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4133G>T p.C1378F 4:105269698-105269698 0
19 COSM4383952 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4519C>T p.Q1507* 4:105272900-105272900 0
20 COSM87169 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4249G>T p.V1417F 4:105272630-105272630 0
21 COSM42029 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3646C>T p.R1216* 4:105243621-105243621 0
22 COSM1168028 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.2191C>T p.Q731* 4:105236133-105236133 0
23 COSM87108 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2692G>T p.G898* 4:105236634-105236634 0
24 COSM110754 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4106C>G p.S1369* 4:105269671-105269671 0
25 COSM42036 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3571C>T p.Q1191* 4:105242904-105242904 0
26 COSM5879027 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3896A>C p.K1299T 4:105259711-105259711 0
27 COSM6023743 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5636A>G p.E1879G 4:105276146-105276146 0
28 COSM4383929 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3954G>C p.E1318D 4:105259769-105259769 0
29 COSM211727 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4019T>G p.L1340R 4:105261823-105261823 0
30 COSM42016 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4393C>T p.R1465* 4:105272774-105272774 0
31 COSM100071 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4471A>T p.K1491* 4:105272852-105272852 0
32 COSM6023746 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3873G>A p.W1291* 4:105259688-105259688 0
33 COSM100058 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4333C>T p.Q1445* 4:105272714-105272714 0
34 COSM7342040 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3819T>G p.C1273W 4:105259634-105259634 0
35 COSM43420 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4546C>T p.R1516* 4:105275056-105275056 0
36 COSM7342034 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3805A>T p.R1269* 4:105259620-105259620 0
37 COSM43417 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.2746C>T p.Q916* 4:105236688-105236688 0
38 COSM7342035 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4402A>T p.K1468* 4:105272783-105272783 0
39 COSM7342042 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4069G>T p.E1357* 4:105269634-105269634 0
40 COSM7342041 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3320C>G p.S1107* 4:105237262-105237262 0
41 COSM6987090 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3817T>C p.C1273R 4:105259632-105259632 0
42 COSM5708963 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.3500G>T p.R1167M 4:105241429-105241429 0
43 COSM100070 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.2887C>T p.Q963* 4:105236829-105236829 0
44 COSM6023745 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.4707C>A p.Y1569* 4:105275217-105275217 0
45 COSM4766109 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.2861G>A p.W954* 4:105236803-105236803 0
46 COSM4766169 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.3500G>A p.R1167K 4:105241429-105241429 0
47 COSM6933803 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.4075C>A p.R1359S 4:105269640-105269640 0
48 COSM5945026 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.2233C>T p.Q745* 4:105236175-105236175 0
49 COSM43499 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.5693C>T p.S1898F 4:105276203-105276203 0
50 COSM41741 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.5618T>C p.I1873T 4:105276128-105276128 0

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell costimulation GO:0031295 9.16 ICOS PDCD1
2 cytokine production GO:0001816 8.96 ITK MAF
3 germinal center formation GO:0002467 8.62 BCL6 CXCL13

Molecular functions related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.62 ITK SYK

Sources for Angioimmunoblastic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....